Levothyroxine linked to short-term creatinine improvement in hypothyroid inpatients
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Very Low
Zhao T, Zhang N, Tian Y, et al.
Sep 8, 2026 · Published in: Frontiers in Endocrinology
Thyroid hormone therapy reverses renal dysfunction in hypothyroidism.
Omnipod 5 sustains glycemic gains over 12 months in adults
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Renard E, Weinstock RS, Penfornis A, et al.
Aug 31, 2026 · Published in: Endocrinology, Diabetes & Metabolism
The Omnipod 5 System enhances and sustains diabetes control long-term.
Emerging Pharmacotherapy Landscape for MASLD and MASH
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Straatmijer T, Mulder M
Aug 28, 2026 · Published in: British Journal of Clinical Pharmacology
Innovative treatments for MASLD target diverse pathways.
Pharmacotherapy Reshapes Obstructive Sleep Apnea Management Toward Endotype-Driven Care
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Zhou R, Yin G, Zhu Y, et al.
Aug 27, 2026 · Published in: Journal of Clinical Medicine
New drug options show promise for improving sleep apnea treatment beyond CPAP.
Sitagliptin Beats Pioglitazone for Stringent HbA1c Targets in Triple Therapy
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Kim TH, Hwang Y, Woo S, et al.
Aug 22, 2026 · Published in: Medicine
Sitagliptin outperforms pioglitazone in metabolic outcomes for T2DM.
DOACs Outperform Warfarin for VTE in Morbid Obesity
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Shi J, Zhang Y, Tang Y, et al.
Aug 22, 2026 · Published in: Medicine
DOACs might outperform warfarin for VTE in morbid obesity.
Deintensification Doubled But Still Lags in Overtreated Older Diabetics
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Le P, Guo N, Misra-Hebert AD, et al.
Aug 10, 2026 · Published in: JAMA Internal Medicine
Exploring medication changes for older adults with diabetes.
GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Matsuo Y, Okada A, Sakamoto T, et al.
Aug 9, 2026 · Published in: Diabetes, Obesity & Metabolism
GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.
SGLT2 Inhibitors Show No Significant Serious UTI Excess
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Matteucci A, Di Fusco SA, Bonanni M, et al.
Aug 7, 2026 · Published in: Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
SGLT2 inhibitors show no significant rise in UTI risk.
TRAVERSE: Testosterone Is CV-Safe, But Safety Signals and Overdiagnosis Remain
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
What the TRAVERSE trial actually shows, what it does not, and why pharmacists need to address the 'Low T' marketing phenomenon.
GLP-1 RAs: Evidence-Based Prescribing vs. The Compounded Peptide Crisis
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
Navigating legitimate GLP-1 RA controversies alongside the safety crisis in compounded and unregulated peptide products.
From Glucose-Centric to Outcomes-Driven: ADA 2026 Reshapes Diabetes Therapy
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
How GLP-1 RAs and SGLT2 inhibitors displaced metformin as the default first-line in type 2 diabetes management.
Emerging Anti-Obesity Targets Extend Beyond Incretin Pharmacotherapy
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Very Low
Lee S, Song H, Kwon Y
Jul 28, 2026 · Published in: Pharmaceuticals (Basel, Switzerland)
Innovative anti-obesity drugs offer hope beyond current treatments.
Empagliflozin Modestly Improves Liver Enzymes in MASLD, Not Lipids
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Karimi M, Tahmasebi A, Ramezanipour S, et al.
Jul 27, 2026 · Published in: Endocrinology, Diabetes & Metabolism
Empagliflozin reduces liver enzymes in MASLD patients, showing promise.
Complementary SGLT2 Inhibitor Plus GLP-1 Agonist Therapy in Type 2 Diabetes
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Porterfield LR, Nadeem S, Swanson D, et al.
Jul 18, 2026 · Published in: Current Atherosclerosis Reports
Combining SGLT2is and GLP-1RAs may revolutionize diabetes management.